期刊文献+

含EWS-FLI1结合序列的DTA载体对报告基因表达抑制的研究 被引量:1

DTA vector containing the binding sequence of EWS-FLI1 depresses the activation of luciferase
下载PDF
导出
摘要 目的 研究含尤文家族肿瘤EWS FLI1结合序列的DTA载体对报告基因表达的抑制作用。方法 构建含有EWS FLI1结合序列和白喉毒素A链基因的表达载体 pS2 DTA。共同转染不同剂量梯度的 pS2 DTA和pS2到尤文肉瘤细胞和对照细胞 ,检测荧光强度。结果 每增加一个 pS2 DTA剂量梯度 ,在尤文肉瘤细胞中都可以检测到虫荧光素酶的表达显著降低 ,而在对照细胞中这种作用却不明显 ;在同一个pS2 DTA剂量梯度下 ,虫荧光素酶在尤文肉瘤细胞的表达都显著高于非尤文肉瘤细胞。结论 pS2 DTA转染可以抑制尤文肉瘤细胞内其它基因表达。 Objective To study the DTA vector containing the Ewing family of tumor's EWS-FLI1 binding sequence depresses the co-transferred luciferase reporter plasmid.Methods To construct the DTA expression vector (pS2-DTA), the luciferase gene in pS2 was replaced with DTA gene at the points of NcoⅠand XbaⅠ by molecular technique. To compare the activation of luciferase, pS2 and pS2-DTA were co-transferred into cultured Ewing's sarcoma cell (SK-ES) and control cell (Hela).Results The luciferase activity in Ewing's sarcoma cells was significantly depressed, with the high concentration of pS2-DTA. The expression of luciferase is higher in SK-ES than that in Hela at the same concentration.Conclusions The pS2-DTA can depress the activation of luciferase, and this function is stronger when concentration of pS2-DTA co-transferred.
出处 《重庆医学》 CAS CSCD 2004年第12期1848-1850,共3页 Chongqing medicine
基金 国家自然科学基金资助项目 (30 1 0 0 1 89)
关键词 尤文家族肿瘤 融合基因 白喉毒素A链 虫荧光素酶 Ewing family of tumor fusion gene diphtheria toxin A fragment (DTA) luciferase
  • 相关文献

参考文献10

  • 1Foss FM. Diphtheria toxin fusion proteins[J]. Curr Top Microbiol Immunol,1998,234: 63
  • 2Panchal RG. Novel therapeutic strategies to selectively kill cancer cell[J]. Biochem Pharmacol,1998,55: 247
  • 3Lin PP, Rachel I, Ladanyi, et al. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma[J]. Cancer Res,1999,59 (7): 1428
  • 4May WA, Lessnic SL, Braun BS, et al. The Ewing's sarcoma EWS-FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1[J]. Mol Cell Biol,1993,13:7393
  • 5Turc Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. An evaluation of 85 cases and remarkable consistency of t(11;22)(q24;q12)[J]. Cancer Genet Cytogenet,1988,32: 229
  • 6Mao XH, Susan Miesfeldt,Yang HD, et al. The FLI-1 and chimeric EWS-FLI-1 oncoprotein display similar DNA binding specificities[J].J Biol Chem,1994,269 (27): 18216
  • 7Kreitman RJ. Immunotoxins in cancer therapy[J]. Curr Opin Immunol,1999,11(5):570
  • 8Hagihara N. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107[J]. Cancer Res,2000,60 (2): 230
  • 9Wawarynczak EJ. Systemic immunotoxintherapy of cancer: advances and prospects[J]. Br J Cancer,1991,64 (5): 624
  • 10West. Ewing sarcoma family of tumors[J]. Curr Opin Oncol,2000,12(4): 323

同被引文献9

  • 1Descotes J. Methods of evaluating immunotoxicity[J]. Expert Opin Drug Metab Toxicol, 2006,2(2):249.
  • 2Pastan I, Hassan R, Fitzgerald DJ, et al. Immunotoxin therapy of cancer [J]. Nat Rev Cancer, 2006, 6 (7):559.
  • 3Chin KM, Foss FM. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox [J]. Clin Lymphoma Myeloma, 2006, 7(3):199.
  • 4Foss FM, Waldmann TA. Interleukin-2 receptor-directed therapies for cutaneous lymphomas [J]. Hematol Oncol Clin North Am, 2003,17(6): 1449.
  • 5Li F,Yang XX, Xia HC,et al. Purification and characterization of Luffin P1, a ribosome-inactivating peptide from the seeds of Luffa cylindrical [J]. Peptides, 2003,24(6):799.
  • 6Wood DE, Newccmb EW. Cleavage of Bax enhances its cell death function [J]. Exp Cell Res, 2000, 256 (2): 375.
  • 7Yoshioka Y,Tsutsumi Y, Nakagawa S, et al. Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach [J]. Curr Vasc Pharmacol, 2004, 2(3): 259.
  • 8Foss FM, Osann K. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lyrnphoma: decreased frequency and severity with steroid premedication [J]. Clin Lymphoma, 2001, 1(4):298.
  • 9Querfeld C, Rosen ST, Guitart J, et al. Phase Ⅱ trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sezary syndrome [J]. J Am Acad Dermatol, 2007,56(4):580.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部